


Tungsten nanoparticle and polymer blends as novel coating for ragiopaque resorbable inferior vena cava filters

Erin San Valentin¹, Jossana Damasco¹, Marvin Bernardino¹, Sarah Honegger^{1,2}, Karem Court³, Biana Godin³, William Norton⁴, Stephen Chen¹, Natalie Fowlkes⁴, Steven Huang¹, and Marites P. Melancon¹

¹Departments of Interventional Radiology and ⁴Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 ²Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556 ⁴Department of Nanomedicine. Houston Methodist Research Institute, Houston TX 77030

Background

Deep vein thrombosis (DVT) or pulmonary embolism (PE) affects about 900,000 individuals annually in the United States¹. Currently, management is primarily through employment of anticoagulation therapy; however, placement of inferior vena cava filters (IVCFs) is recommended for patients with contraindications to anticoagulation. Absorbable IVCFs constructed with poly-pdioxanone (PPDO) eliminate the need for filter retrieval. Radiolucency of PPDO-IVCFs can be improved with radio-enhancing nanoparticles (NPs).



1. Tungsten (W) NPs reinforced with Fig. polyhydroxybutyrate (PHB), polyvinylpyrrolidone (PVP) and polycaprolactone (PCL) polymer blends as a novel coating for commercially available PPDO IVC filters.


E)


B)

C)


С


Results





measured using alamarBlue assay after 24h incubation in varying ratios of treated cell culture media.





Making Cancer History®




Fig. 6. Gross images from necropsy (top), H&E (middle), and polarized light histology (bottom) images of IVCaffected area of WNP+ PHB (left) and WNP+PHB+PCL+PVP (right) filters. Scale bar = 1mm

Conclusion

- In vitro cytotoxicity and hemolysis assay did not show any effects on W-IVCF.
- Bioresorbable IVCFs coated with WNPs

Methods

WNPs were synthesized by thermal decomposition of tungstic acid with oleic acid, oleylamine, and 1-octadecene as stabilizers under an Ar blanket. Physicochemical collected WNPs properties were of transmission/scanning characterized by electron microscopy (TEM/SEM), microcomputed tomography (CT), dynamic light scattering (DLS) and powder X-ray diffraction (XRD) patterns. PPDO sutures and IVC filters were coated with WNPs with PHB, PCL, and PVP using a wet-dipping technique.

In vitro cell viability and hemolysis assays were done using immortalized human vascular endothelial cells (EC-RF24) and erythrocytes from laboratory rats, respectively.

W+PHB and W+PHB+PCL+PVP IVCFs were deployed in separate pig models, monitored, and imaged using CT for 12 weeks. Post-mortem histology analyses were done to investigate possible systemic and local effects of WNP+polymer-embedded IVCFs.




Fig. 2. Schema for the synthesis and characterization of WNP-IVCF and implantation in pigs.

Fig. 5. (A) Photographs, X-ray images, and micro-CT images of the control PPDO, WNP+PHB, and WNP+PHB+PCL+PVP IVCFs. (B) Fluoroscopy-guided placement of WNP+PHB and WNP+PHB+PCL+PVP filters. Blue arrows indicate the tip and the bottom of the IVCF. (C-D) In vivo CT monitoring of WNP+PHB and WNP+PHB+PCL+PVP filters over a period of 12 weeks.

- and PHB+PCL+PVP reinforcement can be fully visualized in pigs under fluoroscopy and CT for real-time image-guided deployment and monitoring over time.
- Despite good visualization in fluoroscopy and CT from deployment until week 12, lumen of the WNP+PHB+PCL+PVPcoated IVCF pig did not seem to recover from initial inflammation as reflected by closed and necrotic lumen.

Future Direction

Although the addition of biocompatible polymers, PHB, PCL, and PVP enhanced the attachment of WNPs which resulted in increased radiopacity, localized inflammatory response was also observed in histology. Therefore, alternative polymers are currently being investigated to increase the surface roughness of PPDO and attachment of the nanoparticles. In addition, other high-Z nanoparticles, such as zirconium and gadolinium, are also being explored as potential radiopaque agents for IVCFs.

References

1) Beckman et al. Am J Prev Med. 2010;38(4 Suppl):S495-501 2) Fletcher, S. et al. Curr Treat Options Cardio Med. 2021;23,14 3) Tian et al. Proc SPIE Int Soc Opt Eng. 2018; 10576 4) Damasco et al. ACS Biomater Sci Eng. 2022; 8: 1676-1685

Acknowledgements

This study has been supported in part by grants from NIH-NHLBI (1R01HL141831-01; 1R01HL159960-01A1), NIH-NCI (CA016672), and the Dunn Foundation.